Lucid Diagnostics Inc. (LUCD)

US — Healthcare Sector
Peers: NARI  XAIR  PAVMZ  CLPT  OSA  LIVN  ELMD  KIDS  SRDX  NPCE  FNA  CVRX  LUNG  IRMD  OFIX  ITGR 

Automate Your Wheel Strategy on LUCD

With Tiblio's Option Bot, you can configure your own wheel strategy including LUCD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LUCD
  • Rev/Share 12.0841
  • Book/Share -78.1582
  • PB -0.0155
  • Debt/Equity -6.5594
  • CurrentRatio 0.753
  • ROIC 6.9626

 

  • MktCap 130915478.0
  • FreeCF/Share -181.654
  • PFCF -0.0105
  • PE -0.0023
  • Debt/Assets 1.0755
  • DivYield 0
  • ROE 26.959

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript
LUCD
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2025 Business Update Conference Call May 14, 2025 8:30 AM ET Company Participants Matt Riley – Senior Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – Chief Financial Officer Conference Call Participants Mark Massaro – BTIG Kyle Mikson – Canaccord Genuity Mike Matson – Needham & Company Jeremy Pearlman – Maxim Group Ross Osborn – Cantor Fitzgerald Ed Woo – Ascendiant Capital Operator Good morning and welcome to the Lucid Diagnostics First Quarter 2025 Business Update Conference Call. Please note, this event is being recorded.

Read More
image for news Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
LUCD
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Negative

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.21 per share a year ago.

Read More
image for news Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know
LUCD
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
LUCD, PAVM
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.

Read More
image for news Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
LUCD, PAVM
Published: April 11, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.20 per share. The total net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $16.1 million.

Read More
image for news Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
LUCD, PAVM
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , April 3, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D. , Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT.

Read More
image for news Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
LUCD, PAVM
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral

Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference NEW YORK , March 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will be prominently featured at Digestive Disease Week (DDW) …

Read More
image for news Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
LUCD, PAVM
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral

Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a recent update to the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) focused on Esophageal and Esophagogastric Junction Cancers (Version 1.2025) has added a new section on esophageal precancer (Barrett's Esophagus or BE) screening. The NCCN Guidelines® now reference professional …

Read More
image for news Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
LUCD, PAVM
Published: March 10, 2025 by: PRNewsWire
Sentiment: Neutral

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.

Read More
image for news Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

About Lucid Diagnostics Inc. (LUCD)

  • IPO Date 2021-10-14
  • Website https://www.luciddx.com
  • Industry Medical - Devices
  • CEO Dr. Lishan Aklog M.D.
  • Employees 72

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.